Key facts
- This page summarizes Laureen DeBuono's Form 4 filing for Rani Therapeutics Holdings, Inc. (RANI).
- 4 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 17 Dec 2024, 17:00.
Laureen DeBuono - 16 Dec 2024 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)
- Reporting relationship
- Director
- Issuer ticker
- RANI
- Reported as of
- 16 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Dec 2024, 17:00:07 UTC
- Prior SEC filing
- 30 May 2024
- Source filing
- View source filing
- Reporting owner signature
- Svai Sanford. Attorney-in-Fact for Laureen DeBuono
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Laureen DeBuono filed Form 4 for Rani Therapeutics Holdings, Inc. (RANI) on 17 Dec 2024.
Change
- Previous filing in this sequence was filed on 30 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RANI
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -101,276
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Dec 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 101,276
- Exercise price
- $2.84
- Footnotes
- F1
RANI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +101,276
- Change %
- Price
- Shares after
- 101,276
- Date
- 16 Dec 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 101,276
- Exercise price
- $4.11
- Footnotes
- F1
RANI
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -18,875
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Dec 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 18,875
- Exercise price
- $2.84
- Footnotes
- F2, F3
RANI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +18,875
- Change %
- +16%
- Price
- Shares after
- 135,896
- Date
- 16 Dec 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 18,875
- Exercise price
- $9.44
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options.
Footnote F2
The shares subject to the option vested as follows: 1/3rd of the shares subject to the option vested on April 20, 2022; and 1/36th of the shares subject to the option vested monthly over the following two years.
Footnote F3
On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options.